OR WAIT 15 SECS
Catalent licenses Excelimmune’s antibody combination therapy platform toenable the manufacture of multiple recombinant antibodies in a single batch culture.
Catalent has signed a licensing agreement with Excelimmune to access its antibody combination therapy technology platform, which has the potential to enable a consistent and cost-effective method to manufacture multiple recombinant antibodies or other recombinant proteins in a single batch culture, the company reported on July 7.
Under the licensing agreement, Catalent will continue development work on the platform, both internally and in conjunction with partner-sponsored programs. Catalent will also leverage its proprietary GPEx technology to help enable that development.
Excelimmune's antibody combination expression system is based on the use of stable pools of cells generated by multiple directed gene insertions, instead of clonal cell lines. This attribute contributes to a quick, stable, and flexible culture system for mixtures of cells producing different antibodies. This technology has the potential to pave the way for more consistent, cost-effective production of antibody combinations, which will allow complex antibody therapeutics to gain greater accessibility to the clinic.